Table 1 Selected characteristics and bone mineral density (BMD) by serum adiponectin quartiles.
Adiponectin at baseline | Q 1 (N = 94) (< 8.82) Mean (SD) /NO (%) | Q 2 (N = 94) (8.82–11.95) Mean (SD) /NO (%) | Q 3 (N = 94) (11.96–15.87) Mean (SD) /NO (%) | Q 4 (N = 94) (≥ 15.88) Mean (SD) /NO (%) | P-value |
|---|---|---|---|---|---|
Age (yr) | 55.4 (3.9) | 55.0 (3.8) | 55.3 (3.4) | 55.0 (3.8) | 0.816 |
BMI | 23.5 (2.6) | 22.8 (2.6) | 22.5 (2.4) | 22.0 (2.1) | 0.0004 |
Menopausal duration (yr) | 5.5 (2.7) | 5.5 (2.6) | 4.8 (2.4) | 5.1 (2.6) | 0.225 |
History of hysterectomy | 12 (12.8%) | 10 (10.6%) | 9 (9.6%) | 9 (9.6%) | 0.88 |
History of diabetes | 1 (1.1%) | 0 | 0 | 2 (2.1%) | |
History of hypertension | 21 (22.3%) | 13 (13.8%) | 11 (11.7%) | 12 (12.8%) | 0.158 |
History of hyperlipidemia | 54 (57.5%) | 49 (52.1%) | 42 (44.7%) | 31 (33.0%) | 0.005 |
Cigarette smoking | 0 | 1 (1.1%) | 0 | 0 | |
Habitual alcohol consumption | 2 (2.1%) | 3 (3.2%) | 4 (5.3%) | 4 (5.3%) | 0.89 |
Isoflavon treatment | 44 (46.8%) | 47 (50.0%) | 50 (53.2%) | 48 (51.1%) | 0.85 |
Daily physical activity (total METs/week) | 3719 (1106) | 4179 (1566) | 4592 (2139) | 4865 (1895) | < 0.001 |
Daily energy intake (Kcal) | 1512 (352) | 1577 (374) | 1586 (347) | 1519 (352) | 0.475 |
Daily calcium intake (mg) | 460 (212) | 533 (221) | 493 (181) | 537 (238) | 0.121 |
Lumbar spine BMD (g/cm2) | |||||
Baseline | 0.88 (0.08) | 0.89 (0.08) | 0.90 (0.09) | 0.89 (0.10) | 0.754 |
48th week | 0.88 (0.08) | 0.89 (0.08) | 0.89 (0.09) | 0.88 (0.10) | 0.871 |
96th week | 0.87 (0.08) | 0.88 (0.08) | 0.88 (0.09) | 0.88 (0.10) | 0.599 |
Lumbar spine T-score | |||||
Baseline | − 1.89 (0.69) | − 1.94 (0.67) | − 1.97 (0.77) | − 2.06 (0.74) | 0.415 |
48th week | − 1.93 (0.72) | − 1.93 (0.66) | − 2.03 (0.76) | − 2.13 (0.76) | 0.195 |
96th week | − 2.04 (0.70) | − 2.02 (0.65) | − 2.07 (0.74) | − 2.17 (0.78) | 0.523 |
Total proximal femur BMD (g/cm2) | |||||
Baseline | 0.80 (0.08) | 0.78 (0.09) | 0.79 (0.09) | 0.77 (0.10) | 0.233 |
48th week | 0.79 (0.08) | 0.78 (0.09) | 0.79 (0.09) | 0.77 (0.10) | 0.398 |
96th week | 0.79 (0.08) | 0.77 (0.08) | 0.78 (0.09) | 0.76 (0.10) | 0.312 |
Total proximal femur T-score | |||||
Baseline | − 0.90 (0.70) | − 1.07 (0.76) | − 1.08 (0.88) | − 1.40 (0.77) | 0.003 |
48th week | − 0.93 (0.67) | − 1.13 (0.70) | − 1.11 (0.83) | − 1.36 (0.76) | 0.01 |
96th week | − 0.97 (0.71) | − 1.20 (0.74) | − 1.17 (0.84) | − 1.42 (0.78) | 0.01 |
Bone alkaline phosphatase (μg/L) | |||||
Baseline | 16.68 (5.89) | 16.24 (5.83) | 15.48 (5.42) | 16.04 (5.99) | 0.549 |
48th week | 14.94 (5.37) | 14.24 (4.67) | 14.47 (4.76) | 14.82 (4.53) | 0.747 |
96th week | 14.94 (4.69) | 14.59 (4.57) | 14.72 (4.82) | 15.07 (4.52) | 0.901 |
Urinary N-telopeptide of type 1 collagen/creatinitine (nM BCE/mM) | |||||
Baseline | 69.19 (35.6) | 60.26 (27.5) | 64.39 (24.1) | 66.25 (59.8) | 0.468 |
48th week | 64.90 (26.8) | 61.20 (29.7) | 63.60 (26.3) | 70.02 (43.8) | 0.297 |
96th week | 60.13 (24.0) | 59.57 (25.5) | 61.49 (24.5) | 60.30 (25.3) | 0.960 |
